RecruitingNCT06932081

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i (ACHIEVE-SGLT2i) Registry

Sponsor

Leiden University Medical Center

Enrollment

400 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Congenital Heart Disease Adult Congenital Heart Disease Systemic Right Ventricle Transposition of the Great Arteries Congenitally Corrected Transposition of the Great Arteries Fontan Single Ventricle Tetralogy of Fallot (TOF)

Summary

This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This international registry study tracks outcomes in adults with congenital heart disease (heart defects present from birth) who have been prescribed SGLT2 inhibitors — a class of medication originally developed for diabetes that is now being used for heart and kidney conditions. **You may be eligible if...** - You are 18 years or older - You have a congenital heart defect (a heart structural problem present since birth) - You have been newly started on an SGLT2 inhibitor medication (such as dapagliflozin or empagliflozin) **You may NOT be eligible if...** - You do not consent to having your data collected for the registry Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSGLT2 inhibitors

Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.

Locations(11)

Johns Hopkins University

Baltimore, Maryland, United States

Helen DeVos Children's Hospital

Grand Rapids, Michigan, United States

Mount Sinai Fuster Heart Hospital

New York, New York, United States

Heart Center Duisburg (Evangelical Hospital Niederrhein)

Duisburg, Germany

Leiden University Medical Center (LUMC)

Leiden, South Holland, Netherlands

Amsterdam University Medical Center

Amsterdam, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

Zan Mitrev Clinic

Skopje, North Macedonia

University Hospital of Wales

Cardiff, United Kingdom

Golden Jubilee University National Hospital

Glasgow, United Kingdom

Barts Heart Centre

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06932081

Related Trials

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT071147188 locations

Implementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework

NCT075592531 location

HFNC vs NIPPV Following Extubation

NCT058698251 location

NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

NCT066462501 location

Online Support 4 CHD Kids & Caregivers

NCT060752511 location